Back

Thirty-days versus standard duration of dual antiplatelet treatment after percutaneous coronary interventions: a systematic review and meta-analysis

27 August 2022 (17:15 - 18:00)
Organised by:
Congress Presentation Part of: Short and long-term antiplatelet therapy in clinical practice Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Anastasios Apostolos

Royal Brompton and Harefield Hospitals, London (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Short dual antiplatelet therapy duration in high bleeding risk patients undergoing PCI for non-ST-elevation acute coronary syndrome
Doctor D. Cao (Milan, IT)
Abstract Slides
Presentation thumbnail
CYP2C19 loss-of-function alleles and the use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel - a real-world study
Mr M. Ritvos (Helsinki, FI)
Abstract Slides
Presentation thumbnail
Bentracimab demonstrates reversal of antiplatelet effects of ticagrelor: impact of hematocrit and generic versions of ticagrelor in vitro
Professor B. Curry (Memphis, US)
Abstract Slides
Presentation thumbnail
Intravenous antiplatelet therapy with cangrelor vs. tirofiban in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention
Doctor M. Centore (Salerno, IT)
Abstract Slides
Presentation thumbnail
Comparing dual antiplatelet therapy strategies post-acute coronary syndrome: network meta-analysis
Doctor R. Turgeon (Vancouver, CA)
Abstract Slides

Access the full session

Session thumbnail
Short and long-term antiplatelet therapy in clinical practice

The Event

Event poster

ESC Congress 2022

27 August 2022 17:15 CET
You may be interested in
thumbnail
Congress Presentation
One-month dual antiplatelet therapy following stent implantation in patients with acute coronary syndromes and high bleeding risk
thumbnail
Congress Presentation
A very short duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials
thumbnail
Congress Presentation
A shorter duration of dual-antiplatelet therapy for percutaneous coronary intervention following acute coronary syndrome: a meta-analysis of randomized clinical trials

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources